Redeye: Xspray Pharma - Investment Case Materializing
Redeye envisions an exciting period on the horizon for Xspray Pharma following the resolution of the Dasynoc patent litigation with BMS. We consider the settlement a validation of Xspray's technology and perceive a risk reduction associated with the investment case. As a result, we rework our forecasts and DCF, adjusting our fair value range accordingly.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/